PolyPEPI 1018
Alternative Names: PolyPEPI™ 1018; PolyPEPI™ 1018 CRC VaccineLatest Information Update: 02 Sep 2025
At a glance
- Originator Treos Bio
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Colorectal cancer
Most Recent Events
- 02 Sep 2025 TREOS Bio entered into clinical collaboration agreements with Charité University Medicine Berlin and Junshi Biosciences for the initiation of phase II OBERTO-202 trial
- 27 Aug 2025 TREOS Bio plans to initiate a phase II OBERTO-202 trial for Colorectal Cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) (SC)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Colorectal-cancer(Adjunctive treatment, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in USA (SC, Injection)